Added value of a serum proteomic signature in the diagnostic evaluation of lung nodules

Cancer Epidemiology Biomarkers and Prevention

Volumn 21, Issue 5, 2012, Pages 786-792

  Pecot, Chad V ^a   Li, Ming ^a   Zhang, Xueqiong J ^a   Rajanbabu, Rama ^b   Calitri, Ciara ^b   Bungum, Aaron ^c   Jett, James R ^c   Putnam, Joe B ^a,e   Callaway Lane, Carol ^e   Deppen, Steve ^a   Grogan, Eric L ^a,e   Carbone, David P ^a,b   Worrell, John A ^a   Moons, Karel G M ^a,d   Shyr, Yu ^a   Massion, Pierre P ^a,b,e  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e Tennessee Valley Healthcare System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC VALUE; FEMALE; HUMAN; LUNG CANCER; LUNG NODULE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; PROTEOMICS; TUMOR DIAGNOSIS; TUMOR VOLUME;

AGED; COHORT STUDIES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROSPECTIVE STUDIES; PROTEOMICS; RISK FACTORS; SOLITARY PULMONARY NODULE; TUMOR MARKERS, BIOLOGICAL;

EID: 84862849740     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-11-0932     Document Type: Article

References (30)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Marshall E. Cancer screening. The promise and pitfalls of a cancer breakthrough. Science 2010;330:900-1.
3. van Klaveren RJ, Oudkerk M, Prokop M, Scholten ET, Nackaerts K, Vernhout R, et al. Management of lung nodules detected by volume CT scanning. N Engl J Med 2009;361:2221-9.
4. Xu DM, van Klaveren RJ, de Bock GH, Leusveld A, Zhao Y, Wang Y, et al. Limited value of shape, margin and CT density in the discrimination between benign and malignant screen detected solid pulmonary nodules of the NELSON trial. Eur J Radiol 2008;68:347-52.
5. Crestanello JA, Allen MS, Jett JR, Cassivi SD, Nichols FC 3rd, Swensen SJ, et al. Thoracic surgical operations in patients enrolled in a computed tomographic screening trial. J Thorac Cardiovasc Surg 2004;128:254-9. (Pubitemid 38969807)
6. Grogan EL, Stukenborg GJ, Nagji AS, Simmons W, Kozower BD, Jones DR, et al. Radiotracer-guided thoracoscopic resection is a cost-effective technique for the evaluation of subcentimeter pulmonary nodules. Ann Thorac Surg 2008;86:934-40; discussion 40.
7. Swensen SJ, Jett JR, Hartman TE, Midthun DE, Mandrekar SJ, Hillman SL, et al. CT screening for lung cancer: five-year prospective experience. Radiology 2005;235:259-65. (Pubitemid 40432263)
8. Smith MA, Battafarano RJ, Meyers BF, Zoole JB, Cooper JD, Patterson GA. Prevalence of benign disease in patients undergoing resection for suspected lung cancer. Ann Thorac Surg 2006;81:1824-8; discussion 8-9.
9. Veronesi G, Bellomi M, Scanagatta P, Preda L, Rampinelli C, Guarize J, et al. Difficulties encountered managing nodules detected during a computed tomography lung cancer screening program. J Thorac Cardiovasc Surg 2008;136:611-7.
10. Swensen SJ, Silverstein MD, Ilstrup DM, Schleck CD, Edell ES. The probability of malignancy in solitary pulmonary nodules. Application to small radiologically indeterminate nodules. Arch Intern Med 1997;157: 849-55. (Pubitemid 28337035)
11. Gould MK, Ananth L, Barnett PG. A clinical model to estimate the pretest probability of lung cancer in patients with solitary pulmonary nodules. Chest 2007;131:383-8. (Pubitemid 46280396)
12. Schultz EM, Sanders GD, Trotter PR, Patz EF Jr, Silvestri GA, Owens DK, et al.Validation of two models to estimate the probability of malignancy in patients with solitary pulmonary nodules. Thorax 2008;63:335-41. (Pubitemid 351497946)
13. Gould MK, Fletcher J, Iannettoni MD, Lynch WR, Midthun DE, Naidich DP, et al. Evaluation of patients with pulmonary nodules: when is it lung cancer?: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132:108S-30S. (Pubitemid 47502803)
14. Yildiz PB, Shyr Y, Rahman JS, Wardwell NR, Zimmerman LJ, Shakhtour B, et al. Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer. J Thorac Oncol 2007;2:893-901. (Pubitemid 47511591)
15. Moons KG, Biesheuvel CJ, Grobbee DE. Test research versus diagnostic research. Clin Chem 2004;50:473-6. (Pubitemid 38297294)
16. Craig BA, Fryback DG, Klein R, Klein BE. A Bayesian approach to modelling the natural history of a chronic condition from observations with intervention. Stat Med 1999;18:1355-71. (Pubitemid 29261494)
17. Moons KG. Criteria for scientific evaluation of novel markers: a perspective. Clin Chem 2010;56:537-41.
18. Lijmer JG, Bossuyt PM. Various randomized designs can be used to evaluate medical tests. J Clin Epidemiol 2009;62:364-73.
19. Lijmer JG, Leeflang M, Bossuyt PM. Proposals for a phased evaluation of medical tests. Med Decis Making 2009;29:E13-21.
20. Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst 2008;100:1432-8.
21. Godoy MC, Naidich DP. Subsolid pulmonary nodules and the spectrum of peripheral adenocarcinomas of the lung: recommended interim guidelines for assessment and management. Radiology 2009;253: 606-22.
22. MacMahon H, Austin JH, Gamsu G, Herold CJ, Jett JR, Naidich DP, et al. Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society. Radiology 2005;237:395-400. (Pubitemid 41507873)
23. Shyr Y. Statistical Methods. Tumor proteomic patterns predict classification and tumor behavior in human non-small cell lung cancer. [cited 2003]Available from: www.vicc.org/biostatistics/download/lancet/ methods.pdf.
24. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157-72; discussion 207-12.
25. Efron B, Tisbsirani R. An introduction to Bootstrap. New York: Chapman and Hall; 1993.
26. Harrell FE. Regresssion modeling strategies. New York: Springer Verlag; 2001.
27. Yonemori K, Tateishi U, Uno H, Yonemori Y, Tsuta K, Takeuchi M, et al. Development and validation of diagnostic prediction model for solitary pulmonary nodules. Respirology 2007;12:856-62. (Pubitemid 350045718)
28. Beane J, Sebastiani P, Whitfield TH, Steiling K, Dumas Y-M, Lenburg ME, et al. A prediction model for lung cancer diagnosis that integrates genomic and clinical features. Cancer Prev Res 2008;1:56-64.
29. Salmon S, Chen H, Chen S, Herbst R, Tsao A, Tran H, et al. Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimen. J Thorac Oncol 2009;4:689-96.
30. Taguchi F, Solomon B, Gregorc V, Roder H, Gray R, Kasahara K, et al. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst 2007;99:838-46.